Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: CASTRATION-RESISTANT PROSTATE CANCER, . Treffer: 9

2020

Lu, C; Terbuch, A; Dolling, D; Yu, J; Wang, H; Chen, Y; Fountain, J; Bertan, C; Sharp, A; Carreira, S; Isaacs, WB; Antonarakis, ES; De Bono, JS; Luo, J Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
Ann Oncol. 2020;
PubMed FullText FullText_MUG

 

2019

Grubmüller, B; Senn, D; Kramer, G; Baltzer, P; D'Andrea, D; Grubmüller, KH; Mitterhauser, M; Eidherr, H; Haug, AR; Wadsak, W; Pfaff, S; Shariat, SF; Hacker, M; Hartenbach, M Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2019; 46(5):1063-1072 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

de Wit, S; Manicone, M; Rossi, E; Lampignano, R; Yang, L; Zill, B; Rengel-Puertas, A; Ouhlen, M; Crespo, M; Berghuis, AMS; Andree, KC; Vidotto, R; Trapp, EK; Tzschaschel, M; Colomba, E; Fowler, G; Flohr, P; Rescigno, P; Fontes, MS; Zamarchi, R; Fehm, T; Neubauer, H; Rack, B; Alunni-Fabbroni, M; Farace, F; De Bono, J; IJzerman, MJ; Terstappen, LWMM EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.
Oncotarget. 2018; 9(86):35705-35716 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

El-Heliebi, A; Hille, C; Laxman, N; Svedlund, J; Haudum, C; Ercan, E; Kroneis, T; Chen, S; Smolle, M; Rossmann, C; Krzywkowski, T; Ahlford, A; Darai, E; von Amsberg, G; Alsdorf, W; König, F; Löhr, M; de Kruijff, I; Riethdorf, S; Gorges, TM; Pantel, K; Bauernhofer, T; Nilsson, M; Sedlmayr, P In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells.
Clin Chem. 2018; 64(3):536-546 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Smith, MR; Saad, F; Chowdhury, S; Oudard, S; Hadaschik, BA; Graff, JN; Olmos, D; Mainwaring, PN; Lee, JY; Uemura, H; Lopez-Gitlitz, A; Trudel, GC; Espina, BM; Shu, Y; Park, YC; Rackoff, WR; Yu, MK; Small, EJ; SPARTAN Investigators Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med. 2018; 378(15): 1408-1418. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Mohamad Al-Ali, B; Kramer, G; Madersbacher, S; Berger, I Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of a medical claims database.
Wien Klin Wochenschr. 2017; 129(11-12):380-384 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2016

Kaushik, AK; Shojaie, A; Panzitt, K; Sonavane, R; Venghatakrishnan, H; Manikkam, M; Zaslavsky, A; Putluri, V; Vasu, VT; Zhang, Y; Khan, AS; Lloyd, S; Szafran, AT; Dasgupta, S; Bader, DA; Stossi, F; Li, H; Samanta, S; Cao, X; Tsouko, E; Huang, S; Frigo, DE; Chan, L; Edwards, DP; Kaipparettu, BA; Mitsiades, N; Weigel, NL; Mancini, M; McGuire, SE; Mehra, R; Ittmann, MM; Chinnaiyan, AM; Putluri, N; Palapattu, GS; Michailidis, G; Sreekumar, A Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer.
Nat Commun. 2016; 7(7):11612-11612 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Kaushik, AK; Vareed, SK; Basu, S; Putluri, V; Putluri, N; Panzitt, K; Brennan, CA; Chinnaiyan, AM; Vergara, IA; Erho, N; Weigel, NL; Mitsiades, N; Shojaie, A; Palapattu, G; Michailidis, G; Sreekumar, A Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.
J Proteome Res. 2014; 13(2):1088-1100 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2012

Lee, DJ; Cha, EK; Dubin, JM; Beltran, H; Chromecki, TF; Fajkovic, H; Scherr, DS; Tagawa, ST; Shariat, SF Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
BJU Int. 2012; 109(7): 968-985. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

© Med Uni Graz Impressum